Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.91 +0.44 (+3.84%)
Delayed Quote Updated: 1:50 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Appoints Kelley Boucher as Chief People Officer
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch ↗
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial... 
Via MarketBeat
Topics Cannabis Government
Compass Pathways (NASDAQ:CMPS) Shares Plunge 42% After Q2 Report Despite Narrower-Than-Expected Loss ↗
Via Chartmill
News headline image
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances ↗
Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter,... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears ↗
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a... 
Via MarketBeat
Topics Cannabis Government
News headline image
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Investor Conferences the Week of September 14th
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
COMPASS Pathways (CMPS) Q2 2026 Earnings Call Transcript ↗
COMP360 shows 39% response rate; commercial launch targeted for H1 2027. 
Via The Motley Fool
Topics Earnings
News headline image
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth... 
Via MarketBeat
Topics Government
News headline image
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Issued on behalf of Helus Pharma (Nasdaq: HELP) 
From USA News Group
Via GlobeNewswire
News headline image
Compass Pathways Q2 Earnings Call Highlights ↗
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following... 
Via MarketBeat
Topics Cannabis Earnings Government
News headline image
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market. 
Via The Motley Fool
Topics ETFs Government
News headline image
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know. ↗
Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline. 
Via The Motley Fool
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up ↗
Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for... 
Via MarketBeat
Topics Cannabis Government
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.